Winning Advantages of Recombinant Antibodies – completely Reproducible, Made to be Specific
The use of recombinant antibody generation methods is suited for high specificity, reproducibility and scalability.
How Recombinant Antibodies are Created
The process of making a recombinant antibody begins with the introduction of both heavy and light antibody chain clones, specific for their immunity, into a mammalian expression vector with high yield. The vectors that are formed as a result are inserted into hosts like bacteria, yeasts or mammals, for expression, so that functional antibodies of high quality may be manufactured.
In vitro recombinant antibody generation occurs by cloning ScFV or Fab, to form an immunoglobulin network or frame. It can also be created from an already existing hybridoma. When the latter technique is used, the most commonly used models are mouse, rat and rabbit, but almost any species may be employed as long as the right oligonucleotide primers are to hand.
Why use Recombinant Antibodies?
The use of recombinant antibodies is beneficial when compared to the standard polyclonal or monoclonal antibodies, as shown below:
Higher Reproducibility and more Consistent Performance
The process of generating recombinant antibodies using a unique set of genes ensures that the production of antibodies occurs in a dependable and regulated manner. This prevents many issues which occur during hybridoma production, like gene loss or mutations, and drift of the cell line. The end result is minimal variability between batches, and thus extreme reproducibility.
Enhanced Sensitivity and Specificity
With the use of recombinant technology, the sensitivity and specificity of the antibody can be boosted much more easily by engineering the antibody. Since the clone to be used can be selected at two stages, namely, the hybridoma and the recombinant cloning stages, the best qualities can be selected for the antibody.
Once the isolation of the antibody genes is complete, the expression of the antibody can be scaled up or down with greater ease and in a shorter time than conventional monoclonal techniques. As a result, the time required to create custom antibodies is cut to weeks instead of months.
High Throughput Without Animal Testing
Following the isolation of the antibody-creating gene, in vitro antibody generation can be employed.
Recombinant RabMAb® Antibodies
Abcam has produced engineered recombinant antibodies which present the latest versions of the RabMAb rabbit monoclonals. This enables researchers to have access to the best possible sensitivity as well as consistently performing antibodies.
To find out more about why recombinant RabMAb is better, click here.
For a full list of all recombinant RabMAb antibodies, click here.
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.